A U.S. district court found key claims of a Scale Biosciences patent invalid for inadequate written description and enablement, handing Parse Biosciences a win in an ongoing infringement dispute. The patent covered split‑pool barcoding kits for cells and organelles; the ruling follows prior successful challenges to related patents in the single‑cell space. The decision reduces near‑term legal overhang for Parse and may affect competitive dynamics in the single‑cell market, where toolmakers and platform providers increasingly litigate to protect barcoding and library‑preparation intellectual property. The case underscores continued patent friction as startups and established firms commercialize instrument‑free single‑cell chemistries.